NCT06595706View on ClinicalTrials.gov

Evaluating the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 28, 2024

Primary Completion Date

January 24, 2025

Study Completion Date

January 24, 2025

Conditions

Heathy Participants

Interventions

DRUG

Lucid-21-302

Capsule containing a small molecule inhibitor of hypercitrullination

DRUG

Placebo

Capsule containing only Silicified Microcrystalline Cellulose

Trial Locations (1)

5000

Cmax Clinical Research, Adelaide

All Listed Sponsors

lead

Huge Biopharma Australia Pty Ltd

INDUSTRY

NCT06595706 - Evaluating the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 in Healthy Adult Participants | Biotech Hunter | Biotech Hunter